Interesting read: Bristol-Myers Squibb Co. (BMY)
Post# of 72447
(Total Views: 371)
Posted On: 09/05/2019 9:26:12 AM
Interesting read: Bristol-Myers Squibb Co. (BMY) on Thursday said a phase 3 study evaluating the addition of its cancer drug Opdivo to the current standard of care to treat a form of the aggressive tumor glioblastoma multiforme didn't meet the primary endpoint of progression-free survival.
The New York biopharmaceutical company, which remains blinded to the data, said the study's data monitoring committee recommended the trial continue as planned to allow the other primary endpoint, overall survival, to mature.
Bristol-Myers said the study involves the addition of Opdivo to the chemotherapy drug temozolomide and radiation therapy in patients with newly diagnosed glioblastoma multiforme that is O6-methylguanine-DNA methyltransferase-methylated.
Glioblastoma multiforme is the most common and most aggressive type of primary malignant tumor of the central nervous system.
Go IPIX!!!
Opdivo, which harnesses the body's immune system to fight cancer, has been approved for use in several types of cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 05, 2019 07:51 ET (11:51 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
The New York biopharmaceutical company, which remains blinded to the data, said the study's data monitoring committee recommended the trial continue as planned to allow the other primary endpoint, overall survival, to mature.
Bristol-Myers said the study involves the addition of Opdivo to the chemotherapy drug temozolomide and radiation therapy in patients with newly diagnosed glioblastoma multiforme that is O6-methylguanine-DNA methyltransferase-methylated.
Glioblastoma multiforme is the most common and most aggressive type of primary malignant tumor of the central nervous system.
Go IPIX!!!
Opdivo, which harnesses the body's immune system to fight cancer, has been approved for use in several types of cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 05, 2019 07:51 ET (11:51 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
(0)
(0)